Search clinical trials for: bimatoprost ophthalmic solution 0.03%

Total 1663 results

Allergan

Completed

Long-Term Safety of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

Spain, France, Belgium, Israel, United Kingdom, Poland, Italy, Czechia, Germany, Hungary
Allergan

Completed

Safety and Efficacy Study of Different Formulations of Bimatoprost Once-Daily in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Ethnically Japanese Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Different Formulations of Bimatoprost Ophthalmic Solution in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Ophthalmic Solution in Increasing Eyelash Prominence

Eyelash Hypotrichosis

United States
Allergan

Completed

Safety and Efficacy of Three Formulations of AGN-210669 Ophthalmic Solution Compared With Bimatoprost Ophthalmic Solution

Ocular Hypertension | Glaucoma, Open-Angle

United States
Amneal Pharmaceuticals, LLC
CBCC Global Inc.; Amneal EU, Limited

Not yet recruiting

A Randomized, Double-blind, Parallel-group, Two-arm, Multiple Dose, Multicenter, Bioequivalence Study With Clinical Endpoint in the Treatment of Subjects With Chronic Open-angle Glaucoma or Ocular Hypertension in Both Eyes

Ocular Hypertension | Open-angle Glaucoma

United States
Allergan

Completed

Safety and Efficacy of AGN 210669 Ophthalmic Solution in Patients With Ocular Hypertension or Primary Open-Angle Glaucoma

Ocular Hypertension | Glaucoma

United States
Amneal Pharmaceuticals, LLC
CBCC Global Research

Recruiting

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% and LUMIGAN® in the Treatment of Chronic Open-Angle Glaucoma or Ocular Hypertension in Both Eyes.

Ocular Hypertension | Glaucoma, Open-Angle

United States
Mankind Pharma Limited
CBCC Global Research

Completed

Bioequivalence Study With Clinical Endpoint Comparing Bimatoprost Ophthalmic Solution 0.01% to LUMIGAN® In The Treatment of Chronic Open-Angle Glaucoma (Glaucoma)

Glaucoma, Open-Angle

United States
Allergan

Completed

Study Assessing Patient Satisfaction With LATISSE® for Increasing Eyelash Prominence

Hypotrichosis

United States
Tulane University
Allergan

Completed

Topical Bimatoprost for Chemical Blepharoplasty

Dermatochalasis

United States
Gian Sagar Medical College and Hospital

Withdrawn

Topical Bimatoprost Solution 0.03%in Stable Vitiligo

Vitiligo | Repigmentation
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Treating Eyelash Loss or Hypotrichosis in Children

Alopecia Areata | Eyelash Hypotrichosis

United States, Brazil
Allergan

Completed

A Study of Lumigan® 0.01% in Patients With Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Glaucoma, Open-Angle

Austria
Allergan

Completed

Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Switzerland
Allergan

Completed

Observational Study of Lumigan® 0.01% for Treatment of Primary Open Angle Glaucoma (POAG) or Ocular Hypertension (OHT)

Ocular Hypertension | Open-Angle Glaucoma

Belgium
Aerie Pharmaceuticals

Completed

Ocular Hypotensive Efficacy of AR-102

Glaucoma

United States
Alcon Research

Completed

Phase II Safety and Efficacy Study to Evaluate a Glaucoma Therapy in Open-angle Glaucoma or Ocular Hypertension Patients

Ocular Hypertension | Open-angle Glaucoma
Aerie Pharmaceuticals

Completed

Efficacy and Systemic Safety of Netarsudil 0.01%, 0.02%, 0.04% Relative to Placebo in Subjects With Open-angle Glaucoma or Ocular Hypertension in Japan

Ocular Hypertension | Open Angle Glaucoma

Japan
Laboratoires Thea

Completed

Safety and Efficacy Assessment of Monoprost® in Comparison With Lumigan® 0.01 % and Lumigan® 0.03% Unit Dose

Primary Open Angle Glaucoma | Ocular Hypertension

France
Alcon Research

Completed

An Efficacy and Tolerability Study of TRAVATAN® Versus LUMIGAN®

Ocular Hypertension | Glaucoma
Allergan

Completed

A Safety Study of Bimatoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Study of Bimatoprost Solution in Increasing Eyelash Prominence in African Americans With Eyelash Hypotrichosis

Hypotrichosis

United States
Aerie Pharmaceuticals

Completed

Study of AR-13324 in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Alcon Research

Completed

Assessment of Intraocular Pressure (IOP) Control in Subjects With Open-Angle Glaucoma or Ocular Hypertension Treated With Travoprost 0.004% (TRAVATAN® Z) or Bimatoprost 0.01% (LUMIGAN®)

Ocular Hypertension | Glaucoma | Open-Angle Glaucoma
Allergan

Completed

Ocular Surface Tolerability Study of Prostaglandin Analogues in Patients With Open-Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma, Open-Angle

Canada, United States
Allergan

Completed

Bimatoprost in the Treatment of Eyelash Hypotrichosis

Idiopathic Eyelash Hypotrichosis

Russian Federation, Sweden, United States, United Kingdom
Assiut University

Unknown

Bimatoprost 0.03% Solution With NB-UVB Versus Their Use With Fractional Carbon Dioxide Laser in Treatment of Generalized Vitiligo

Generalized Vitiligo
University of California, San Francisco

Completed

Efficacy Study of Latanoprost and Bimatoprost Solutions in Promoting Eyelash Growth in Patients With Alopecia Areata

Alopecia Areata

United States
Innovative Medical

Completed

Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost

Glaucoma

United States
Aerie Pharmaceuticals

Completed

Study Assessing Safety and Efficacy of PG324 Ophthalmic Solution in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Timolol Ophthalmic Solution in Patients With Open Angle Glaucoma or Ocular Hypertension

Ocular Hypertension | Open-angle Glaucoma

China
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Chemotherapy-Induced Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
VivaVision Biotech, Inc

Completed

A Phase 2 Double-masked Study of VVN539 in Subjects With Elevated Intraocular Pressure

Glaucoma, Open-Angle

United States
Singapore National Eye Centre
Allergan

Unknown

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

Glaucoma, Angle-Closure

Singapore
Allergan

Completed

Safety and Efficacy Study of Bimatoprost in Japanese Patients With Eyelash Hypotrichosis

Eyelash Hypotrichosis

Japan
Jonsson Comprehensive Cancer Center

Withdrawn

Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Breast Cancer | Alopecia

United States
Aerie Pharmaceuticals

Completed

Study of Netarsudil Ophthalmic Solution in Japanese/Japanese-American Subjects With Open-angle Glaucoma or Ocular Hypertension

Primary Open Angle Glaucoma or Ocular Hypertension

United States
Allergan

Completed

Safety and Efficacy Study of Bimatoprost to Treat Hypotrichosis of the Eyelashes After Application to the Eyelid Margin

Hypotrichosis

United States, United Kingdom
Allergan

Completed

A Study of Patients With Primary Open Angle Glaucoma or Ocular Hypertension Switched to Lumigan® UD Monotherapy for Medical Reasons

Ocular Hypertension | Glaucoma, Primary Open Angle

Germany
Aerie Pharmaceuticals

Completed

Study Comparing the Safety and Efficacy of AR-13324 to Latanoprost in Patients With Elevated Intraocular Pressure

Ocular Hypertension | Open Angle Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Compared With Latanoprost in Patients With Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Summa Health System

Completed

The Effects of Xalatan, Travatan and Lumigan on Skin Pigmentation Near the Eye

Glaucoma | Application Site Pigmentation Changes

United States
Allergan

Completed

A Safety and Efficacy Study of Fixed-Combination Bimatoprost and Brimonidine in Chronic Glaucoma or Ocular Hypertension

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Safety and Efficacy of Bimatoprost Solution in Increasing Overall Eyelash Prominence

Eyelashes

United States, Canada
Allergan

Completed

Safety and Patient Satisfaction With GLASH VISTA™ (Bimatoprost 0.03%) in the Treatment of Eyelash Hypotrichosis in Japan

Eyelash Hypotrichosis

Japan
Allergan

Completed

Bimatoprost 0.03% Versus Travoprost 0.004% in Patients Currently on Latanoprost 0.005%

Ocular Hypertension | Glaucoma

United States
Pfizer's Upjohn has merged with Mylan to form Viatris...

Completed

Comparison of Latanoprost With Travoprost and Bimatoprost in Patients With Elevated IOP. A 12-weeks, Masked Evaluator, Phase IV Multi-center Study in the US (XLT)

Ocular Hypertension | Glaucoma

United States
Allergan

Completed

Comparing Safety and Efficacy of Combigan® and Lumigan® With Lumigan® Alone in Glaucoma or Ocular Hypertension Subjects Treated With Xalatan®

Ocular Hypertension | Glaucoma

United States

3

Subscribe